Metabolic syndrome is defined by a combination of risk factors that can lead to greater potential of type 2 diabetes, obesity, lipid disorders, cardiovascular disease, and other circulatory disorders. There is currently a significant research focus to understand the key pathways that control metabolism, as these pathways would be likely targets of risk factors (e.g., exposure to xenobiotics, genetics) and lifestyle factors (e.g., microbiome, nutrition, and exercise). Understanding these pathways also can lead to the development of pharmaceutical interventions. Individuals with metabolic syndrome have signs similar to that of toxic responses (e.g., oxidative stress and inflammation) and organ dysfunction. Given the rapidly growing incidence of this syndrome, it is critical to understand these widespread abnormalities as it changes our definition of “normal.” This syndrome can be driven by fat accumulation around intra-abdominal sites (possibly driven by genetic and epigenetic factors leading to predisposition of retaining fat at this site due to poor intra-uterine growth), organ impairment (e.g., non-alcoholic fatty liver disease), and exposure to xenobiotics. While the causes for escalation in the individual risk factors are multiple and complex, there is no clear recognition of the bridges that unite these risk factors to yield increased disease. Indeed, it is likely that there are pathways that are of importance to controlling metabolism that would be targets of both environmental chemicals and pharmaceutical interventions. A multidisciplinary approach to understand the underlying biological mechanisms and translate that knowledge into prevention and treatment is required.
This conference will examine, in the morning, current knowledge on metabolic diseases including developmental aspects and challenges in therapeutic strategies for associated diseases. A poster session during lunch will provide a forum for data and hypothesis exchange. The afternoon will be devoted to a discussion of mechanisms thought to play important roles in the syndrome/diseases and provide insight into drugs and environmental agents thought to influence them. Our focus on understanding the pathways and risk factors leading to disease and how these pathways can be perturbed to develop drugs for disease interventions creates a unique combination that is likely to lead to new thought processes and scientific collaborations in addition to defining knowledge gaps, identifying research needs, protecting public health, and empowering product development.
The specific objectives of this conference include the following:
The CCT: Metabolic Syndrome and Associated Diseases: From Bench to Clinic will be held on March 11, 2017, at the Baltimore Convention Center, 1 W Pratt Street, Baltimore, Maryland
Attendees can book hotel rooms by using the SOT Housing website for the 2017 SOT Annual Meeting. By using the SOT Housing Service, attendees receive discounted hotel room rates and personalized services not available via other methods. Should you have a problem reserving your accommodations, please contact Jay Pierce at Connections Housing, 404.918.9129.
We welcome both junior and senior scientists to present and share their results. Please contact SOT Headquarters if you have any questions regarding the meeting abstracts.
Submit an Abstract (SOT Members are encouraged to log in to have the form pre-populate your contact information.)
The abstract submission system is open until 11:59 PM ET on March 1, 2017. Additional information for speakers, graduate students, and postdoctoral scholars will be available at that time.
|8:45 AM–9:00 AM||Introductions, Overview, and Goals of the Conference
Donna Mendrick, PhD, US FDA/NCTR, Silver Spring, Maryland
|9:00 AM–10:00 AM||Keynote Lecture—Metabolic Diseases: Clinical Manifestations, Role of Genetics, and Lifestyles
Anna Mae Diehl, MD, Florence McAlister Professor of Medicine, Duke University, Durhan, North Carolina
The keynote lecture will provide an overview of the metabolic syndrome and some of its causative modalities and end with a focus on liver damage.
|10:00 AM–11:15 PM||Plenary Session I—Developmental Aspects Related to Metabolic Disease
Speakers will discuss the effects of metabolic dysfunction on normal development.
Chair: Kenneth L. Hastings, MPH, DrPH, Hastings Toxicology Consulting LLC, Mount Airy, Maryland
|10:00 AM–10:30 AM||Obesity in Children: Underlying Causes and Consequences
Lisa Swartz Topor, MD, MMSc, Alpert Medical School, Brown University, Providence, Rhode Island
|10:30 AM–10:45 AM||Break|
|10:45 AM–11:15 AM||Development of Neuroendocrine Systems Governing Energy Homeostasis
Sebastien Bouret, PhD, Keck School of Medicine, University of Southern California, Los Angeles, California
|11:15 AM–12:45 PM||Plenary Session II—Diseases Associated with Metabolic Syndrome and Challenges in Therapeutic Strategies
Metabolic syndrome is associated with many pathologies and, in itself, is a “toxic” environment. This session will focus on some examples of such diseases and challenges seen in drug development.
Chair: Thaddeus Schug, PhD, NIEHS, Research Triangle Park, North Carolina
|11:15 AM–11:45 AM||Overview of Metabolic Syndrome Associated Obesity and Treatments
Jorge Plutzky, MD, Harvard Medical School, Boston, Massachusetts
|11:45 AM–12:15 PM||Drug Development for Treatment of Diabetes: Experiences with Preclinical Tumor Findings for an SGLT2 Inhibitor
Mark D. Johnson, PhD, Janssen Pharmaceutical Company, Raritan, New Jersey
|12:15 PM–12:45 PM||Overview of Cardiovascular Disease and Drug Development
Norman Stockbridge, MD, PhD, US Food and Drug Administration/Center for Drug Evauation and Research, Silver Spring, Maryland
|12:45 PM–2:15 PM||Lunch and Poster Session|
|2:15 PM–5:15 PM||Plenary Session III—Cellular Mechanisms and Pathophysiology
The sessions above will acquaint the audience with some of the mechanisms behind these abnormalities, the similarity with environmental agents, and the influence of the microbiome.
Chair: Susan G. Emeigh Hart, VMD, PhD, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut
|2:15 PM–2:45 PM||Mitochondrial Dysfunction and Metabolic Syndrome—Are Genetics, Drug, and Environmental Toxins Responsible?
Yvonne Will, PhD, Pfizer, Groton, Connecticut
|2:45 PM–3:15 PM||Fat As an Inflammatory Tissue
Rodney R. Dietert, PhD, Cornell University, Ithaca, New York
|3:15 PM–3:45 PM||Metaorganismal Endocrinology: Gut Microbial Metabolites as Postprandial Hormones Impacting Metabolic Disease Effects
Jonathan Mark Brown, Cleveland Clinic, Lerner Research Institute, Cleveland, Ohio
|3:45 PM–4:00 PM||Break|
|4:00 PM–4:30 PM||Environmental Agents and Drugs That May Affect Metabolic Syndrome and Associated Diseases
Michele La Merrill, PhD, University of California Davis, Davis, California
|4:30 PM–5:00 PM||Risk Assessment of Environmental Agents
Carrie R. Fleming, PhD, Dow AgroSciences, Indianapolis, Indiana
|5:00 PM–5:30 PM||Wrap Up and Discussion
Florence Burleson, PhD, BRT Burleson Research Technologies, Inc., Morrisville, North Carolina
|Scientific Liaison Coalition (SLC) Member||$220||$250|
Fees include all general sessions, program materials, and refreshments throughout the course of the meeting.
Registration fees may be paid by check (please list all registrants on the check stub), money order, credit card (Visa, MasterCard, Diner’s Club, or American Express), or by a US Government Purchase Order (check must be drawn from the US Department of the Treasury). Please use the registration form. All wire transfers should include an additional $40 processing fee.
Note: For individuals who are not members of SOT, participation in SOT’s CCT—Metabolic Syndrome and Associated Diseases is available only to bona fide individuals who are engaged in or promote the field of toxicology or biotechnology research and support the growth and development of the toxicology field. For organizations, participation in the SOT’s CCT—Metabolic Syndrome and Associated Diseases is available only to bona fide organizations with public policy positions and business practices that are generally consistent with SOT’s mission, goals, reputation, and its policies and principles as determined by SOT. SOT reserves the right to review applications for participation at SOT’s CCT—Metabolic Syndrome and Associated Diseases to confirm that the applicant meets these criteria and may, at the SOT’s sole discretion, reject a registration by an individual or business or withdraw registration privileges at any time if any individual or organization is found to be inconsistent with SOT’s principles and interests.
NOTE: To prevent double-billing, if you are registering by fax, DO NOT mail your original registration form. SOT needs only one copy for processing.
Registration Cancellation Refund Policy: All requests for cancellations and/or refunds must be received in writing to SOT Headquarters by February 10, 2017. These refunds will be processed, less a $30 fee, following the Meeting.
Disabled Attendees: If you need special assistance for this meeting, please contact SOT Headquarters at 703.438.3115.
For information about becoming a meeting supporter, please contact SOT at email@example.com.
BRT Burleson Research Technologies Inc
National Institute of Environmental Health Sciences (NIEHS)
American College of Toxicology (ACT)
Society of Toxicologic Pathology (STP)
Endorsed by the Endocrine Society